FDA Guidance on Digital Health Technologies (DHTs) for Remote Data Acquisition

The FDA guidance on digital health technologies for remote data acquisition—formally titled Digital Health Technologies for Remote Data Acquisition in Clinical Investigations — Guidance for Industry, Investigators, and Other Stakeholders (Final Guidance, December 2023, read 2026-11-10 at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations)—defines the regulatory evidentiary standards required when wearable sensors, mobile applications, ambient room sensors, or remote clinical outcome platforms capture trial endpoints outside brick-and-mortar investigative sites. Produced jointly by CDER, CBER, CDRH, and the Oncology Center of Excellence in fulfillment of PDUFA VII commitments, the December 2023 Final Guidance governs how sponsors select, verify, validate, and manage wearable devices and Digital Health Technologies (DHTs) across both traditional and decentralized clinical trials (DCTs).

What does the FDA’s December 2023 Final Guidance on Digital Health Technologies (DHTs) for Remote Data Acquisition in Clinical Investigations require?

The FDA defines a Digital Health Technology (DHT) as a system that uses computing platforms, connectivity, software, and/or sensors for healthcare and related uses. Critically, a DHT used to measure a clinical trial endpoint (such as a wrist triaxial accelerometer quantifying moderate-to-vigorous physical activity or a patch ECG sensor detecting atrial fibrillation burden) does not necessarily have to be cleared (`510(k)`) or approved (`PMA`) as a marketed medical device prior to use in an IND clinical drug trial, provided it meets fit-for-purpose evidentiary requirements and applicable Investigational Device Exemption (`21 CFR Part 812`) rules.

Across Sections III through VI of the December 2023 Final Guidance, regulatory submissions incorporating DHT data must address six core submission modules:

1. Selection and Description of the DHT (`Section III.A–B`): Technical specification of hardware sensors, firmware version, operating system dependencies, data transmission architecture, and physical form factor suitable for the trial population’s age, motor function, and cognitive baseline.
2. Verification, Validation, and Usability (`Section III.C`): Documented benchtop, analytical, clinical, and human-factors evidence proving the DHT accurately and reliably measures the clinical event or characteristic of interest in the intended context of use.
3. Evaluation of Clinical Endpoints (`Section III.D`): Justification linking the DHT-derived digital biomarker or endpoint to a clinically meaningful outcome (how a patient feels, functions, or survives), distinguishing novel digital endpoints from established clinical biomarkers captured remotely.
4. Statistical Analysis and Trial Design (`Section III.E`): Specification of the trial estimand under ICH E9(R1) (read 2026-11-10 at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical), explicitly pre-specifying minimum valid wear-time thresholds (e.g., >=10 hours/day for >=4 days/week) and strategies for handling DHT-specific intercurrent events (device non-compliance, battery exhaustion, transmission dropouts, or firmware/algorithm updates).
5. Risk Considerations and Informed Consent (`Section III.F`): Cybersecurity/privacy disclosures, third-party End-User License Agreement (EULA) review so participants do not inadvertently waive rights, and safety monitoring protocols specifying whether continuous physiological streams are monitored in real time or analyzed retrospectively.
6. Record Protection and Retention (`Section III.G` & October 2024 Part 11 Guidance): Preservation of the first durable electronic record (whether stored on the sensor/gateway or cloud ingestion server) together with an immutable 21 CFR Part 11 audit trail and metadata linking each data stream to the specific participant and DHT identifier.

How does the FDA define Verification, Validation, and Usability evaluations for wearable sensors and mobile apps used as trial endpoints?

Section III.C of the FDA December 2023 Final Guidance aligns directly with the three-stage V3 Framework (Verification, Analytical Validation, and Clinical Validation) published by the Digital Medicine Society (Goldsack et al., NPJ Digit Med 2020;3:55, read 2026-11-10 at https://www.nature.com/articles/s41746-020-0260-4), and adds an explicit fourth pillar—Usability Evaluations—to ensure real-world participant adherence in wearable health monitoring protocols.

Evaluation Stage	FDA December 2023 Definition & DiMe V3 Alignment	Concrete Evidence Required in IND/IDE Submission
1. Verification (Hardware / Sensor Level)	Confirmation by examination and objective benchtop evidence that the physical analog-to-digital sensor fulfills specified physical parameter requirements.	Shaker-table acceleration linearity (`±g`), optical photoplethysmography (PPG) wavelength stability, sampling rate accuracy (`Hz`), temperature drift, battery life, and waterproof/environmental tolerance.
2. Analytical Validation (Algorithm -> Physiological Construct)	Confirmation that the processed sensor signal and locked software algorithm accurately and precisely measure the physiological or behavioral parameter in human participants.	Concordance against a gold-standard reference method (e.g., wearable patch ECG vs. 12-lead Holter ECG; wrist actigraphy step/sleep algorithm vs. video-monitored treadmill or polysomnography) across diverse skin tones, BMI ranges, and movement speeds.
3. Clinical Validation (Parameter -> Clinical State)	Confirmation that the measured digital parameter meaningfully reflects, identifies, or predicts the clinical condition, functional status, or disease severity in the target clinical population.	Evidence in patients with the target disease (e.g., Parkinson’s disease bradykinesia or heart failure functional capacity) demonstrating sensitivity to change, test-retest reliability, and clinically meaningful within-patient change thresholds.
4. Usability Evaluation (Participant Human Factors)	Confirmation that enrolled trial participants (or caregivers) can correctly wear, charge, synchronize, and interact with the DHT in unsupervised home environments without introducing measurement error.	Formative or summative usability studies in representative cohorts assessing sensor placement errors, charging compliance, mobile app navigation, and readability.

What are the regulatory and statistical requirements for Bring Your Own Device (BYOD) vs. sponsor-provisioned DHTs in decentralized clinical trials?

In Section III.A.2 of the December 2023 Final Guidance, the FDA addresses when trial sponsors allow participants to use their personal smartphones, tablets, or commercial smartwatches—a deployment model known as Bring Your Own Device (BYOD) for research data collection—versus shipping standardized, sponsor-provisioned hardware to every participant.

While BYOD improves participant convenience and reduces wear-compliance drop-off, the FDA requires sponsors to evaluate and mitigate four technical risks before permitting BYOD for primary or key secondary trial endpoints:

• Hardware and Operating System Heterogeneity: Different smartphone models (iOS vs. Android OEMs) contain different accelerometers, gyroscopes, microphones, cameras, and screen dimensions. Sponsors must define minimum hardware/OS specifications in the protocol and demonstrate via verification/validation studies that measurement performance is equivalent across all permitted device tiers.
• Equity and Provisioned Backup Option: To prevent socioeconomic selection bias, the FDA recommends that any trial utilizing a BYOD model also maintain a sponsor-provisioned device inventory for eligible participants who do not own a compatible device or adequate cellular/Wi-Fi data plan.
• Unscheduled Operating System and Firmware Updates (`Section III.G.4`): Consumer smartphones and commercial wearables push automatic over-the-air OS and firmware updates that can alter power management, background Bluetooth polling, or sensor filtering mid-trial. Sponsors must maintain a change-management monitoring process, version-stamp every ingested record with the exact DHT firmware and algorithm version, and perform bridging analyses if an update alters signal characteristics.
• End-User License Agreements (EULAs) and Data Privacy: When commercial consumer wearables or apps are used, sponsors must review manufacturer terms of service to ensure trial participants are not forced to accept commercial EULAs that conflict with the IRB-approved informed consent document or expose identifiable trial health data.

Frequently Asked Questions

What does the FDA’s December 2023 Final Guidance on Digital Health Technologies (DHTs) for Remote Data Acquisition in Clinical Investigations require?

The December 2023 Final Guidance requires sponsors to justify DHT selection for the target patient population, submit Verification, Validation, and Usability evidence, link the digital measure to a clinically meaningful endpoint, pre-specify `ICH E9(R1)` estimands and missing-data rules for non-wear or technical dropouts, address safety monitoring and EULA/privacy risks in informed consent, and preserve the first durable electronic record with Part 11 audit trails.

How does the FDA define Verification, Validation, and Usability evaluations for wearable sensors and mobile apps used as trial endpoints?

Verification confirms physical sensor accuracy on the benchtop (e.g., sampling rate, linearity); Validation comprises Analytical Validation (confirming the algorithm accurately measures the physiological/behavioral construct against a reference standard in humans) and Clinical Validation (confirming the measure reflects clinical status in the target disease population); and Usability confirms participants can operate and wear the DHT correctly at home.

What are the regulatory and statistical requirements for Bring Your Own Device (BYOD) vs. sponsor-provisioned DHTs in decentralized clinical trials?

For BYOD deployments, sponsors must define minimum hardware/OS requirements, demonstrate measurement equivalence across permitted device models, provide sponsor-provisioned backup devices so participants without compatible hardware are not excluded, log exact OS/firmware versions on every record, and account for device heterogeneity and unscheduled updates in the statistical analysis plan.